BridgeBio Pharma BBIO Accrued research and development liabilities
Accrued research and development liabilities at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accrued research and development liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accrued research and development liabilities?
- BridgeBio Pharma (BBIO) reported accrued research and development liabilities of $12.99M in Q1 2026.
- How has BridgeBio Pharma's accrued research and development liabilities changed year-over-year?
- BridgeBio Pharma's accrued research and development liabilities increased by 2124.0% year-over-year, from -$642K to $12.99M.
- What does accrued research and development liabilities mean?
- The change in unpaid costs related to research and development activities.
- How do you interpret accrued research and development liabilities?
- An increase suggests the company is deferring cash payments for R&D services, while a decrease indicates settlement of these research obligations.
- How does accrued research and development liabilities compare across companies?
- Highly specific to R&D-heavy industries like biotechnology and pharmaceuticals.